SCHEMBL4711911

SCHEMBL4711911

Nc1cccc(-c2cs[c]n2)c1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RECQL P46063 2/20 0.50
TSHR P16473 1/20 0.50
ALDH1A1 P00352 5/20 0.46
MEN1 O00255 4/20 0.46
KDM4E B2RXH2 4/20 0.46
MAPT P10636 4/20 0.46
KMT2A Q03164 3/20 0.46
LMNA P02545 3/20 0.46
HPGD P15428 3/20 0.46
METAP2 P50579 1/20 0.45
MAOA P21397 1/20 0.44
NPC1 O15118 3/20 0.42
RAB9A P51151 3/20 0.42
GLA P06280 2/20 0.42
MAP4K4 O95819 3/20 0.42
NFKB1 P19838 1/20 0.41
NFKB2 Q00653 1/20 0.41
RELA Q04206 1/20 0.41
TP53 P04637 2/20 0.41
PSIP1 O75475 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6050957 0.79 KDM4E (0.51) ALDH1A1MEN1KDM4EMAPTKMT2A
SCHEMBL468087 0.79 CYP19A1 (0.45) MAPTMAOANPC1RAB9AGAA
SCHEMBL7228532 0.79 RAB9A (0.51) TSHRALDH1A1MEN1MAPTKMT2A
SCHEMBL1915009 0.79 IDO1 (0.45) TSHRALDH1A1MEN1KDM4EMAPT
SCHEMBL17626009 0.77 ALDH1A1 (0.40) ALDH1A1MEN1KDM4EMAPTKMT2A
SCHEMBL70645 0.77 ALDH1A1 (0.42) ALDH1A1MEN1KDM4EMAPTKMT2A
SCHEMBL3277855 0.76 IDO1 (0.50) ALDH1A1MEN1KDM4EKMT2AHPGD
SCHEMBL8124238 0.76 IDO1 (0.35) ALDH1A1MEN1KDM4EMAPTKMT2A
SCHEMBL17626006 0.76 HTR7 (0.43) ALDH1A1MEN1KDM4EKMT2AHPGD
SCHEMBL17625998 0.75 SMN1; SMN2 (0.44) TSHRALDH1A1KDM4EMAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1248612-B1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA LTD (CA) 2008-02-27 EP disclosed
EP-1248612-A4 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2005-09-07 EP disclosed
US-6525036-B2 Treating post-menopausal osteoporosis. MERCK & CO., INC. 2003-02-25 US disclosed
EP-1248612-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC. (CA) 2002-10-16 EP disclosed
WO-2002070519-A1 MONOBACTAMS AS CATHEPSIN K INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2002-09-12 WO disclosed
US-20020052378-A1 Novel compounds and compositions as protease inhibitors Celera Corporation 2002-05-02 US disclosed
WO-2001049288-A9 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA INC (CA) 2001-10-25 WO disclosed
WO-2001049288-A1 NOVEL COMPOUNDS AND COMPOSITIONS AS PROTEASE INHIBITORS MERCK FROSST CANADA & CO. (CA) 2001-07-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020052378-A1 Novel compounds and compositions as protease inhibitors SERPINB1, CTRL, SPINT2 RECQL 2892/4885TSHR 4785/4885ALDH1A1 1987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.